[go: up one dir, main page]

MX2016009667A - Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma. - Google Patents

Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.

Info

Publication number
MX2016009667A
MX2016009667A MX2016009667A MX2016009667A MX2016009667A MX 2016009667 A MX2016009667 A MX 2016009667A MX 2016009667 A MX2016009667 A MX 2016009667A MX 2016009667 A MX2016009667 A MX 2016009667A MX 2016009667 A MX2016009667 A MX 2016009667A
Authority
MX
Mexico
Prior art keywords
crystal form
monobenzoate
compound
preparation
pharmaceutical composition
Prior art date
Application number
MX2016009667A
Other languages
English (en)
Other versions
MX366651B (es
Inventor
Li Tongshuang
Tan Songde
Wang Weibo
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of MX2016009667A publication Critical patent/MX2016009667A/es
Publication of MX366651B publication Critical patent/MX366651B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con el campo de preparar compuestos farmacéuticos, en particular se relaciona con una forma cristalina ? del Compuesto A de Monobenzoato, el cual es un inhibidor de DPP-IV, y un método de preparación del mismo, y una composición farmacéutica que comprende la forma cristalina.
MX2016009667A 2014-01-24 2015-01-26 Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma. MX366651B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410037009 2014-01-24
PCT/CN2015/071525 WO2015110077A1 (zh) 2014-01-24 2015-01-26 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物

Publications (2)

Publication Number Publication Date
MX2016009667A true MX2016009667A (es) 2017-02-28
MX366651B MX366651B (es) 2019-07-17

Family

ID=53680849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009667A MX366651B (es) 2014-01-24 2015-01-26 Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.

Country Status (5)

Country Link
CN (1) CN104803971B (es)
BR (1) BR112016017087B1 (es)
MX (1) MX366651B (es)
RU (1) RU2677660C2 (es)
WO (1) WO2015110077A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349215B (zh) * 2015-07-15 2022-02-08 深圳信立泰药业股份有限公司 一种化合物a苯甲酸盐的无定形及其制备方法和含有该无定形的药物组合物
WO2017008684A1 (zh) * 2015-07-15 2017-01-19 深圳信立泰药业股份有限公司 化合物A的晶型α及其制备方法和含有该晶型的药物组合物
WO2018219295A1 (zh) * 2017-05-31 2018-12-06 深圳信立泰药业股份有限公司 二肽基肽酶iv抑制剂的氘代1,2,4-三嗪衍生物
CN109692164A (zh) * 2017-10-20 2019-04-30 深圳信立泰药业股份有限公司 化合物a或其盐的药物组合物及其制备方法
CN115246817B (zh) * 2021-04-28 2024-06-18 深圳信立泰药业股份有限公司 化合物A苯甲酸盐的晶型β及其制备方法和含有该晶型的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
FR2933979B1 (fr) * 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
CA2784799C (en) * 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
CN103068392A (zh) * 2010-05-12 2013-04-24 Mapi医药公司 苯甲酸阿格列汀的多晶形物
CN103172615A (zh) * 2013-03-29 2013-06-26 山东罗欣药业股份有限公司 苯甲酸阿格列汀晶型化合物

Also Published As

Publication number Publication date
RU2677660C2 (ru) 2019-01-18
MX366651B (es) 2019-07-17
WO2015110077A1 (zh) 2015-07-30
BR112016017087B1 (pt) 2022-12-27
BR112016017087A8 (pt) 2018-04-17
RU2016134404A (ru) 2018-03-01
BR112016017087A2 (pt) 2017-08-08
CN104803971A (zh) 2015-07-29
CN104803971B (zh) 2021-11-30
RU2016134404A3 (es) 2018-08-15

Similar Documents

Publication Publication Date Title
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
MX2016012056A (es) Procedimiento de compuesto antifungico.
EP3232790A4 (en) Mixotrophic chlorella-based composition, and methods of its preparation and application to plants
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
MX369357B (es) Procedimiento de compuesto antifungico.
PH12017500737A1 (en) Kcnq2-5 channel activator
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EP3241824A4 (en) Trifluoroacethydrazide compound as well as preparation method therefor and application thereof in preparing medicament
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂
EP3564224A3 (en) Crystalline form of vortioxetine hydrobromide as antidepressant drug
MX2015016603A (es) Composiciones de corticosteroides.
BR112015031820A2 (pt) composto, composição farmacêutica, intermediário, processo para a preparação de um composto e métodos
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
EP3118207A4 (en) Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same
EP3162789A4 (en) Production intermediate of polymerizable compound, method for producing same, composition and stabilization method
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds

Legal Events

Date Code Title Description
FG Grant or registration